Bio

Dr Goldenberg completed training at UCLA, Geisel School of Medicine at Dartmouth, Tufts Medical Center, and Cedars Sinai Medical Center. In addition to a gastroenterology fellowship, he graduated with a Masters in Healthcare Delivery Science at Cedars Sinai Medical Center. He has a passion for medical education and enjoys teaching medical students, residents, and fellows as a Clinician Educator. His research focuses on Healthcare Delivery with an emphasis on maximizing value-based healthcare and medical innovation. He has an additional interest in translational research with multiple publications and patent applications for medical devices. He has unique clinical expertise in fecal microbiota transplantation.

Clinical Focus

  • Gastroenterology
  • General Gastroenterology
  • Colonoscopy
  • Colon Cancer Screening
  • Endoscopy
  • Fecal Microbiota Transplantation

Academic Appointments

Administrative Appointments

  • Director of General Gastroenterology, Stanford University School of Medicine (2023 - Present)

Professional Education

  • Board Certification: American Board of Internal Medicine, Gastroenterology (2020)
  • Fellowship: Cedars Sinai Gastroenterology Fellowship (2020) CA
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2018)
  • Residency: Tufts Medical Center Internal Medicine Residency (2017) MA
  • Medical Education: Dartmouth Geisel School of Medicine Office of the Registrar (2014) NH

Contact

  • Academic
    University - Academic staff Department: Medicine - Med/Gastroenterology and Hepatology Position: Clinical Assistant Professor
  • Clinical (Primary)  Stanford Digestive Health Clinic 420 Broadway St Pavilion D 2nd Fl Redwood City, CA 94063 (650) 498-6323 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 6341

All Publications

  • Delivery of Fecal Material to Terminal Ileum Is Associated with Long-Term Success of Fecal Microbiota Transplantation. Digestive diseases and sciences Weingarden, A. R., Treiger, O., Ulsh, L., Limketkai, B., Goldenberg, D., Okafor, P., Sonu, I., Stollman, N., Neshatian, L. 2022

    Abstract

    BACKGROUND: Fecal microbiota transplantation (FMT) is a highly effective treatment for recurrent Clostridioides difficile infection (CDI). However, 10-20% of patients still fail to recover following FMT. There is a need to understand why these failures occur and if there are modifiable factors that can be addressed by clinicians performing FMT.AIMS: We sought to identify factors related to the FMT procedure itself which could impact FMT outcomes. We also aimed to identify patient demographics which might be associated with FMT outcomes and whether any factors were associated with early FMT failure compared to late CDI recurrence.METHODS: We performed a retrospective multicenter cohort analysis of FMT procedures between October 2005 and November 2020. We collected data on patient demographics, details of the FMT procedure, and procedure outcomes. Using univariate and multivariate regression, we evaluated whether these factors were associated with long-term FMT success, early FMT failure (less than 60days following procedure), or late CDI recurrence (more than 60days following procedure).RESULTS: Long-term success of FMT was strongly correlated with any delivery of stool to the terminal ileum (Odds Ratio [OR] 4.83, 95% confidence interval [CI] 1.359-17.167) and underlying neurologic disease (OR 8.012, 95% CI 1.041-61.684). Lower bowel prep quality was significantly associated with both early FMT failure (p=0.034) and late CDI recurrence (p=0.050).CONCLUSIONS: Delivery of stool to the terminal ileum is significantly associated with long-term success following FMT. This is a relatively safe practice which could easily be incorporated into the standard of care for colonoscopic FMT.

    View details for DOI 10.1007/s10620-022-07761-9

    View details for PubMedID 36372864